EUVIMEDOpdag EUVIMED
Open access · CC BY-NC 4.0

Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL

Yandong Shen iD, Jane A Freeman iD, Ian Kerridge iD, Paul Downe, Kartik Naidu, Juliette Holland, Stephen P Mulligan iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19087 ↗

At a glance

Journal article in British Journal of Haematology, 2024. Written by Yandong Shen and 6 co-authors. Institution: Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia. Major MEDLINE topics: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphocytosis, COVID-19, Vaccines. Cited 3 times so far (Crossref); 15 references. The full text is freely available (open access, CC BY-NC 4.0).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

We analysed COVID‐19 infection outcomes of 129/241 chronic lymphocytic leukaemia (CLL) (53.9%) and 22/55 monoclonal B‐lymphocytosis (MBL) (40.0%) patients following multiple vaccine doses aiming for maximum measured anti‐spike antibody response. Throughout the pandemic to date, there were 8/129 CLL (6.2%) patients hospitalised, with one death (0.8%). No MBL patients were hospitalised or died. CLL patients with COVID‐19 had lower anti‐spike levels (3778.8 AU/mL) than those without (13 486.8 AU/mL; p = 0.0061). Anti‐nucleocapsid antibody was detected in 29.8% within 2 months and 17.5% >6 months. Of COVID‐19‐infected CLL patients, 47.3% received anti‐viral therapy. A multiple vaccine dosing strategy to achieve measured maximum antibody is highly effective in preventing severe COVID‐19.

Subjects

MeSH terms (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphocytosisCOVID-19VaccinesHumansB-LymphocytesCOVID-19 VaccinesAntibody FormationVaccination

Author keywords

CLLCOVID infection outcomeMBLmaximum antibody responsemultiple vaccination

Substances

COVID-19 VaccinesVaccines

Authors and institutions

  • Department of Haematology, Royal North Shore Hospital, St Leonards, New South Wales, Australia.
  • Kolling Institute, Royal North Shore Hospital, University of Sydney, St Leonards, New South Wales, Australia.
  • Department of Haematology and Flow Cytometry, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.
  • Northern Haematology and Oncology Group, Sydney Adventist Hospital, Wahroonga, New South Wales, Australia.
  • Department of Microbiology, Healius Laverty Pathology, Macquarie Park, New South Wales, Australia.

ORCID profiles: Yandong Shen, Jane A Freeman, Ian Kerridge, Stephen P Mulligan

Cite

APA

Shen, Y., Freeman, J. A., Kerridge, I., Downe, P., Naidu, K., Holland, J., & Mulligan, S. P. (2024). Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. https://doi.org/10.1111/bjh.19087

Vancouver

Shen Y, Freeman JA, Kerridge I, Downe P, Naidu K, Holland J, et al. Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL. British Journal of Haematology. 2024. doi:10.1111/bjh.19087

BibTeX
@article{Shen2024,
  author = {Shen, Yandong and Freeman, Jane A and Kerridge, Ian and Downe, Paul and Naidu, Kartik and Holland, Juliette and Mulligan, Stephen P},
  title = {Repeated COVID‐19 vaccination to maximum antibody response yields very low mortality and hospitalisation rates in patients with CLL and MBL},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19087}
}
Start for free →